Tandem Diabetes Care (TNDM) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Tandem Diabetes Care is expected to announce its Q2 2025 earnings on August 6th, forecasting a loss of ($0.40) per share and revenue of $238.39 million.
• The company's previous quarter results showed a miss in earnings estimates, reporting ($0.67) per share against expectations of ($0.60), although revenue was above estimates at $234.42 million.
• Several analysts have downgraded Tandem Diabetes Care's stock ratings, with Citigroup setting a new price target of $14.00, down from $24.00.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $238.39 million for the quarter.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The business had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same period in the previous year, the business posted ($0.65) EPS. Tandem Diabetes Care's revenue was up 22.3% compared to the same quarter last year. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

TNDM stock traded down $0.18 on Friday, reaching $15.40. 1,385,256 shares of the company were exchanged, compared to its average volume of 1,648,595. Tandem Diabetes Care has a 12 month low of $14.31 and a 12 month high of $47.60. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The stock's fifty day moving average price is $18.30 and its 200 day moving average price is $22.32. The firm has a market capitalization of $1.03 billion, a PE ratio of -5.54 and a beta of 1.47.

Hedge Funds Weigh In On Tandem Diabetes Care

Several institutional investors and hedge funds have recently bought and sold shares of TNDM. Dynamic Technology Lab Private Ltd bought a new stake in shares of Tandem Diabetes Care in the first quarter worth about $225,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tandem Diabetes Care by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company's stock valued at $1,426,000 after buying an additional 2,096 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Tandem Diabetes Care by 9.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 193,993 shares of the medical device company's stock worth $3,717,000 after purchasing an additional 16,254 shares in the last quarter. Royal Bank of Canada lifted its holdings in Tandem Diabetes Care by 30.5% during the first quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company's stock worth $4,054,000 after buying an additional 49,408 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Tandem Diabetes Care by 41.1% during the 1st quarter. Millennium Management LLC now owns 227,585 shares of the medical device company's stock valued at $4,361,000 after purchasing an additional 66,245 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TNDM. Wells Fargo & Company reduced their price target on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. Citigroup reiterated a "sell" rating and issued a $14.00 price objective (down from $24.00) on shares of Tandem Diabetes Care in a research report on Wednesday, July 9th. Robert W. Baird reduced their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. Mizuho initiated coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price target on the stock. Finally, Piper Sandler lowered their price objective on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $32.71.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.